Aerosol delivery devices and airways/lung deposition

Inhaled Steroids in Asthma: Optimizing Effects in the Airways

Volumn , Issue , 2016, Pages 169-212

  Dolovich, Myrna B ^a  

^a MCMASTER UNIVERSITY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 85121183191     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.3109/9780203908532-10     Document Type: Chapter

References (164)

1. Lippmann M. Regional deposition of particles in the human respiratory tract. In: Lee DHK, Falk HL, Murphy, SD, eds. Handbook of Physiology, Section 9, Reaction to Environmental Agents. Bethesda, MD: American Physiological Society, 1977:213-232.
2. Dolovich M. Aerosols. In: Barnes PJ, Grunstein MM, Leff AR, Woolcock AJ eds. Asthma. Philadelphia: Lippincott-Raven, 1997:1349-1366.
3. Dolovich M. Influence of inspiratory flow rate, particle size and airway caliber on aerosolized drug delivery to the lung. Respir Care 2000; 45(6):597-608.
4. Dolovich M, Ryan G, Newhouse MT. Aerosol penetration into the lung; influence on airway responses. Chest 1981; 80(6 suppl):834-836.
5. Newman SP, Pavia D, Garland N, Clarke SW. Effects of various inhalation modes on the deposition of radioactive pressurized aerosols. Eur J Respir Dis Suppl 1982; 119:57-65.
6. Parameswaran K. Concepts of establishing clinical bioequivalence of chlorofluorocarbon and hydrofluororcarbon-agonists. J Allergy Clin Immunol 1999; 104:S243-245.
7. Stewart BA, Ahrens RC, Carrier S, Frosolono M, Lux C, Han SH, Milavetz G. Demonstration of in vivo bioequivalence of a generic albuterol metered-dose inhaler to Ventolin. Chest 2000; 117:714-721.
8. Borgström L. The pharmacokinetics of inhaled hydrofluoroalkane formulations. J Allergy Clin Immunol 1999; 104:S246-249.
9. Thorsson L, Edsbäcker S, Conradson TB. Lung deposition of budesonide from Turbuhaler is twice that from a pressurized metered dose inhaler (pMDI). Eur Respir J 1994; 7:1839-1844.
10. Wilson AM, Dempsey OJ, Coutie WJ, Sims EJ, Lipworth BJ. Importance of drugdevice interaction in determining systemic effects of inhaled corticosteroids [letter]. Lancet 1999; 353(9170):2128.
11. Selroos O, Pietinalho A, Riska H. Delivery devices for inhaled asthma medication. Clin Immunother 1996; 6:273-299.
12. Dolovich M. New propellant-free technologies under investigation. J Aerosol Med 1999; 12 (suppl 1):S9-17.
13. Hess DR. Nebulizers: principles and practice. Respir Care 2000; 45:609-622.
14. Nerbrink, O., Dahlback M, Hansson HC. Why do medical nebulizers differ in their output and particle size characteristics? J Aerosol Med 1994; 7:259-276.
15. Dunbar CA, Hickey AJ, Holzner P. Dispersion and characterization of pharmaceutical dry powder aerosols. KONA 1998; (16):7-44.
16. Edsbäcker S. Pharmacological factors that influence the choice of inhaled corticosteroids. Drugs 1999; 58 (suppl 4):7-16.
17. Prime D, Grant AC, Slater AL, Woodhouse RN. A critical comparison of the dose delivery characteristics of four alternative inhalation devices delivering salbutamol:pressurized metered dose inhaler, Diskus inhaler, Diskhaler inhaler, and Turbuhaler inhaler. J Aerosol Med 1999; 12(2):75-84.
18. Laube BL, Georgopoulos A, Adams GK III: Preliminary study of efficacy of insulin aerosol delivered by oral inhalation in diabetic patients. JAMA 1993; 269:2106-2109.
19. Hess DR., Fisher D. Williams P, Pooler S, Kacmarek RM. Medication nebulizer performance:effects of diluent volume, nebulizer flow and nebulizer brand. Chest 1996; 110:498-505.
20. Fok TF, Monkman S, Dolovich M, Gray S, Coates G, Paes B, et al. Efficiency of aerosol medication delivery from a metered dose inhaler versus jet nebulizer in infants with bronchopulmonary dysplasia. Pediatr Pulmonol 1996; 21(5):301-309.
21. Thorsson L, Bisgaard H. Lung deposition of inhaled drugs increases with age. Am J Respir Crit Care Med 2000; 162:1819-1822.
22. Kim CS, Hu SC. Regional deposition of inhaled particles in human lungs: comparison between men and women. J Appl Physiol 1998; 84:1834-1844.
23. Schuster J, Rubsamen R, Lloyd P, Lloyd J. The AERx aerosol delivery system. Pharm Res 1997; 14:354-357.
24. De Young LR, Chambers F, Narayan S, Wu C. The AeroDose multidose inhaler device design and delivery characteristics. In: Dalby RN, Byron PR, Farr SV, eds. Proceedings Respiratory Drug Delivery VI. Buffalo Grove, IL: Interpharm Press, 1998:91-95.
25. Zierenberg B, Eicher J, Dunne S, Freund B. Boehringer Ingelheim nebulizer BINEB® a new approach to inhalation therapy. In: Dalby RN, Byron PR, Farr SJ, eds. Proceedings Respiratory Drug Delivery V. Buffalo Grove, IL: Interpharm Press, Inc, 1996:187-193.
26. Denyer J, Dyche A, Nikander K, Newman S, Richards J, Wilkes B, Dean A. Halolite:a novel liquid drug aerosol delivery system. Thorax 1997; 52(suppl 6):P208.
27. Farr SJ, Schuster JA, Lloyd P, Lloyd LJ, Okikawa JK, Rubsalmen RN. AERx-development of a novel liquid aerosol delivery system: concept to clinic. In: Dalby RN, Byron PR, Farr SJ, eds. Proceedings Respiratory Drug Delivery V. Buffalo Grove, IL: Interpharm Press, Inc., 1996: 175-185.
28. Smaldone GC, Agosti J, Castillo R, Cipolla D, Blanchard J. Deposition of radiolabelled protein from AERx™ in patients with asthma (abstr). J Aerosol Med 1999; 12:98.
29. Newman SP, Brown J, Steed KP, Reader SJ, Kladders H. Lung deposition of fenoterol and flunisolide delivered using a novel device for inhaled medicines: comparison of RESPIMAT with conventional metered-dose inhalers with and without spacer devices. Chest 1998; 113:957-963.
30. De Young LR, Chambers F, Narayan S, Wu C. Albuterol sulphate delivery from the AeroDose liquid inhaler. In: Dalby RN, Byron PR, Farr SJ, eds. Proceedings Respiratory Drug Delivery VI. Buffalo Grove, IL: Interpharm Press, Inc., 1998: 315-318.
31. Denyer J. Adaptive aerosol delivery in practice. Eur Respir Rev 1997; 7:388-389.
32. Nikander K, Bisgaard H. Impact of constant and breath-synchronized nebulization on inhaled mass of nebulized budesonide in infants and children. Pediatr Pulmonol 1999; 28(3):187-193.
33. Mitchell JP, Nagel MW, Archer A. The delivery of budesonide suspension via small volume nebulizers: a comparative in vitro assessment. Chest 1998; 114(suppl 4S):295.
34. Nikander K, Turpeinen M, Wollmer P. Evaluation of pulsed and breath-synchronized nebulization of budesonide as a means of reducing nebulizer wastage of drug. Pediatr Pulmonol 2000; 29:120-126.
35. Nikander K, Agertoft L, Pedersen S. Breath-synchronized nebulization diminishes the impact of patient-device interfaces (face mask or mouthpiece) on the inhaled mass of nebulized budesonide. J Asthma 2000; 37:451-459.
36. Newnham DM, Lipworth BJ. Nebuliser performance, pharmacokinetics, airways and systemic effects of salbutamol given via a novel nebuliser delivery system (“Ventstream”). Thorax 1994; 49:762-770.
37. Nikander K, Turpeinen M, Wollmer P. Evaluation of pulsed and breath-synchronized nebulization of budesonide as a means of reducing nebulizer wastage of drug. Pediatr Pulmonol 2000; 29:120-126.
38. Watterberg KL, Clark AR, Kelly HW, Murphy S. Delivery of aerosolized medication to intubated babies. Pediatr Pulmonol 1991; 10(2):136-141.
39. Clay MM, Pavia D, Newman SP, Clarke SW. Factors influencing the size distribution of aerosols from jet nebulizers. Thorax 1983; 38:755-759.
40. Phipps PR, Gonda I. Droplets produced by medical nebulizers. Some factors affecting their size and solute concentration. Chest 1990; 97:1327-1332.
41. Clay M, Pavia D, Newman SP, Lennard-Jones T, Clarke SW. Assessment of jet nebulizers for lung delivery. Lancet 1983; i:592-594.
42. Ryan G, DolovichM, Obminski G, Cockcroft D, Juniper E, Hargreave F, Newhouse M. Standardization of inhalation provocation tests: influence of nebulizer output, particle size and method of inhalation. J Allergy Clin Immunol 1981; 67(2):156-161.
43. Kradjan WA, Lakshminarayan S. Efficiency of air compressor-driven nebulizers. Chest 1985; 87:512-516.
44. Rubin BK, Nakanishi A, Smith E, Lamb B. Salbutamol by metered dose inhaler plus holding chamber is more effective than salbutamol by jet nebulizer for the treatment of acute childhood asthma. Eur Respir J 1995; 8(suppl 19): 13s.
45. Chou KJ, Cunningham SJ, Crain EF. Metered-dose inhalers with spacers vs nebulizers for pediatric asthma. Arch Pediatr Adolesc Med 1995; 149:201-205.
46. Wildhaber JH, Dore ND, Wilson JM, Devadason SG, LeSouef PN. Inhalation therapy in asthma: nebulizer or pressurized metered-dose inhaler with holding chamber? In vivo comparison of lung deposition in children. J Pediatr 1999; 135:28-33.
47. Hardy JG, Newman SP, Knoch M. Lung deposition from four nebulizers. Respir Med 1993; 87:461-465.
48. Morén F. Aerosol Dosage forms and formulation. In: Morén F, Dolovich MB, Newhouse MT, Newman SP eds. Aerosols in Medicine: Principles, Diagnosis and Therapy. Amsterdam: Elsevier, 1993:321-350.
49. Sanders P. Handbook of Aerosol Technology. New York: Van Nostrand Reinhold, 1979.
50. Clark AR. MDIs: physics of aerosol formulation. J Aerosol Med 1996; 9(suppl 1):S19-S26.
51. June D, Carlson S, Ross D. The effect of temperature on drug delivery characteristics of chlorofluorocarbon (CFC) and hydrofluoroalkane (HFA) metered dose inhalers (MDIs). In: Dalby RN, Byron PR, Farr SJ, eds. Proceedings Respir Drug Delivery V, Buffalo Grove, IL: Interpharm Press, Inc. 1996; 354-356.
52. Leach O. Enhanced drug delivery through reformulating MDIs with HFA propellants-drug deposition and its effect on preclinical and clinical programs. In: Dalby RN, Byron PR, Farr SJ, eds. Proceedings Respir Drug Del V, Buffalo Grove, IL: Interpharm Press, Inc. 1996; 133-144.
53. Schultz RK. Drug delivery characteristics of metered-dose inhalers. J Allergy Clin Immunol 1995; 96:284-287.
54. Cyr TD, Graham SR, Li KYR, Lovering EG. Low first-spray drug content in albuterol metered-dose inhalers. Pharm Res 1991; 8:658-660.
55. Kim CS, Trujillo D, Sackner MA. Size aspects of metered dose inhalers. Am J Respir Crit Care Med 1985; 32:137-142.
56. Wiener MV. How to formulate aerosols to obtain the desired spray pattern. Soc Cos Chem 1958; 9:289-297.
57. Dhand R, Malik SK, Balakrishnan M, Verma SR. High speed photographic analysis of aerosols produced by metered dose inhalers. J Pharm Pharmacol 1988; 40:429-430.
58. Everard M, Dolovich M. In Vivo Measurements of Lung Dose. In: Bisgaard H, O’Callaghan C, Smaldone G, eds. New York: Marcel Dekker, 2001. In press.
59. Campbell LM. Once-daily inhaled corticosteroids in mild to moderate asthma: improving acceptance of treatment. Drugs 1999; 58 (suppl 4):25-33.
60. Crompton GK, Sanderson R, Dewar MH, Matusiewicz SP, Ning AC, Jamieson AH, McLean A, Greening AP. Comparison of Pulmicort pMDI plus Nebuhaler and Pulmicort Turbuhaler in asthmatic patients with dysphonia. Respir Med 2000; 94:448-453.
61. Salzman GA, Pyszczynski DR. Oropharyngeal candidiasis in patients treated with beclomethasone dipropionate delivered by metered-dose inhaler alone and with Aerochamber. J Allergy Clin Immunol 1988; 88:424-428.
62. Selroos O, Backman R, Forsen K-O, Lofroos A-B, Niemisto M, Pietinalho, Aikas C, Riska H. Local side-effects during 4-year treatment with inhaled corticosteoids-a comparison between pressurized metered-dose inhalers and Turbuhaler™. Allergy 1994; 49:888-890.
63. Dolovich M, Ruffin RE, Roberts R, Newhouse MT. Optimal delivery of aerosols from metered dose inhalers. Chest 1981; 80(6 suppl):911-915.
64. Leach CL, Davidson PJ, Boudreau RJ. Improved airway targeting with the CFC-free HFA-beclomethasone metered-dose inhaler compared with CFC-beclomethasone. Eur Respir J 1998; 12(6): 1346-1353.
65. Dolovich MB, Rhem R, Gerrard L, Coates G. Lung deposition of coarse CFC vs fine HFA pMDI aerosols of beclomethasone dipropionate (BDP) in asthma. Am J Respir Crit Care Med 2000; 161(4 Part 2):A62.
66. Conway JH, Walker P, Perkins G, Fleming JS, Holgate ST. Imaging of QVAR lung deposition and distribution in patients with asthma. Eur Respir J 1999; 14(suppl 30):196S, P1360.
67. Devadason SG, Huang T, Turner SW, Walker SL, Troedson R, Le Souef PN. Distribution of 99mTc-labelled HFA-BDP inhaled via Autohaler in children. Eur Respir J 2000; 16(suppl 31):540S (Abstract 3809).
68. Busse WW, Brazinsky S, Jacobson K, Stricker W, Schmitt K, Vanden Burgt J, Donnell D, Hannon S, Colice GL Efficacy response of inhaled beclomethasone dipropionate in asthma is proportional to dose and is improved by formulation with a new propellant. J Allergy Clin Immunol 1999; 104(6):1215-1222.
69. Gross G, Thompson PJ, Chervinsky P, Vanden Burgt J, and the Study Group. Hydrofluoroalkane-134a beclomethasone dipropionate, 400 mg, is as effective as chlorofluorocarbon beclomethasone dipropionate, 800 mg, for the treatment of moderate asthma. Chest 1999; 115:343-351.
70. Dolovich M. Lung dose, distribution and clinical response to therapeutic aerosols. Aerosol Sci Technol 1993; 18:230-240.
71. Dolovich M. Characterization of medical aerosols: physical and clinical requirements for new inhalers. Aerosol Sci Technol 1995; 22:392-399.
72. Barry P, O’Callaghan C. Inhalational drug delivery from seven different spacer devices. Thorax 1996; 96:835-840.
73. Dubus JC, DolovichM. Emitted doses of salbutamol pressurized metered-dose inhaler from five different plastic spacer devices. Fundam Clin Pharmacol 2000; 14:219-224.
74. Ahrens R, Lux C, Bahl T, Han S-H. Choosing the metered-dose inhaler spacer or holding chamber that matches the patient’s need: evidence that the specific drug being delivered is an important consideration. J Allergy Clin Immunol 1995; 96:288-294.
75. Barry PW, O’Callaghan C. The effect of delay, multiple actuations and spacer charge on the in vitro delivery of budesonide from the Nebuhaler. Br J Clin Pharmacol 1995; 40:76-78.
76. Kenyon CJ, Thorsson, Borgström L, Newman SP. The effects of static charge in spacer devices on glucocorticosteroid aerosol deposition in asthmatic patients. Eur Respir J 1998; 11:606-610.
77. Pierart F, Wildhaber JH, Vrancken I, Devadason SG, Le Souef PN. Washing plastic spacers in household detergent reduces electrostatic charge and greatly improves delivery. Eur Respir J 1999; 13: 673-678.
78. Clark DJ, Lipworth BJ. Bioavailability of salbutamol from spacers: effect of multiple actuations, delay, charge reduction on spacer walls. Thorax 1996; 51:981-984.
79. Wildhaber JH, Devadason SG, Hayden MJ, James R, DuftyAP, Fox RA, Summers QA, LeSouef PN. Electrostatic charge on a plastic spacer device influences the delivery of salbutamol. Eur Respir J 1996; 9: 1943-1946.
80. Dompeling E, Oudesluys-Murphy AM, Janssens HM, Hop W, Brinkman JG, Sukhai RN, de Jongste JC. Randomised controlled study of clinical efficacy of spacer therapy in asthma with regard to electrostatic charge. Arch Dis Child 2001; 84:178-182.
81. Dickens GR, Wermeling DP, Matheny CJ, John W, Abramowitz W, Sista SM, Foster T, Choudhury S. Pharmacokinetics of flunisolide administered via metered dose inhaler with and without a spacer device and following oral administration. Ann Allergy Asthma Immunol 2000; 84:528-532.
82. Thorsson L, Kenyon C, Newman SP, Borgstrom L. Lung deposition of budesonide in asthmatics: a comparison of different formulations. Int J Pharm 1998; 168:119-121.
83. Newman SP, Millar AB, Lennard-Jones TR, Moren F, Clarke SW. Improvement of pressurized aerosol deposition with Nebuhaler spacer device. Thorax 1984; 39:935-941.
84. Hindle M, Chrystyn H. Relative bioavailability of salbutamol to the lung following inhalation using metered dose inhalation methods and spacer devices. Thorax 1994; 49:549-553.
85. Lipworth BJ. Airway and systemic effects of inhaled corticosteroids in asthma: dose response relationship. Pulm Pharmacol 1996; 9:19-27.
86. Trescoli C, Ward MJ. Systemic activity of inhaled and swallowed beclomethasone dipropionate and the effect of different inhaler devices. Postgrad Med J 1998; 74:675-677.
87. Newman SP, Weisz AW, Talaee N, Clarke SW. Improvement of drug delivery with a breath actuated pressurised aerosol for patients with poor inhaler technique. Thorax 1991; 46:712-716.
88. Newman SP, Clark AR, Talaee N, Clarke SW. Pressurised aerosol deposition in the human lung with and without an “open” spacer device. Thorax 1989; 44:706-710.
89. Pedersen S. Optimal use of tube spacer aerosols in asthmatic children. Clin Allergy 1985; 15:473-478.
90. Sennhauser FH, Sly PD. Pressure flow characteristics of the valve in spacer devices. Arch Dis Child 1989; 64:1305-1307.
91. Buchdahl R, Ward S, Summerfield A. Letter to the editor: spacer devices in asthma. Thorax 2000; 55:1070.
92. Janssens HM, Heijnen EMEW, de Jong VM, Hop WCJ, Holland WPJ, de Jongste JC, Tiddens HAWM. Aerosol delivery from spacers in wheezy infants: a daily life study. Eur Respir J 2000; 16: 850-856.
93. Dolovich M, Fok TF, Monkman S, Gray S, Rashid F, Paes B, Newhouse M, Kirpalani H. Relationship between infant weight and lung deposition of aerosol. Eur Respir J 1995; 8(suppl 19): 201S.
94. Clark AR. Medical aerosol inhalers: past, present and future. Aerosol Sci Technol 1996; 22:374-391.
95. Ganderton D, Kassem NM. Dry powder inhalers. In: Advances in Pharmaceutical Sciences. London: Academic Press, 1992:165-191.
96. Clark AR, Hollingworth A. The relationship between powder inhaler resistance and peak inspiratory conditions in healthy volunteers-implications for in vitro testing. J Aerosol Med 1993; 6:99-110.
97. Hindle M, Byron PR. Dose emissions from marketed dry powder inhalers. Int J Pharm 1995; 116:169-177.
98. Hinds WC. Aerosol Technology: Properties, Behavior, and Measurement of Airborne Particles. New York: John Wiley & Sons, 1982.
99. Vanbever R, Mintzes JD, Wang J, Nice J, Chen D, Batycky R, Langer R, Edwards DA. Formulation and physical characterization of large porous particles for inhalation. Pharm Res 1999; 16(11):1735-1742.
100. Anderson M, Philipson K, Svartengren M, Camner P. Human deposition and clearance of 6 mm particles inhaled with an extremely low flow rate. Exp Lung Res 1995; 21:187-195.
101. Martonen T, Musante CJ, Segal RA, Schroeter JD, Hwang D, Dolovich M, Burton R, SpencerRM, Fleming J. Lung models: strengths and limitations. Respir Care 2000; 45(6):712-736.
102. Dolovich M, Sanchis J, Rossman C, Newhouse MT. Aerosol penetrance: a sensitive index of peripheral airways obstruction. J Appl Physiol 1976; 40:468-471.
103. Newman SP, Pavia D, Garland N, Clarke SW. Effects of various inhalation modes on the deposition of radioactive pressurized aerosols. Eur J Respir Dis Suppl 1982; 119:57-65.
104. Heyder J, Gebbart J, Rudolf G, Stahlhofen W. Physical factors determining particle deposition in the human respiratory tract. J Aerosol Sci 1980; 11:505-515.
105. Gerrity T. Pathophysiological and disease constraints on aerosol delivery. In: Byron PR, ed. Respiratory Drug Delivery. Boca Raton, FL: CRC Press, Inc., 1990:1-38.
106. Goldin JG, Tashkin DP, Kleerup EC, Greaser LE, Haywood UM, Sayre JW, Simmons MD, Suttorp M, Colice GL, Vanden Burgt JA, Aberle DR. Comparative effects of hydrofluoroalkane and chlorofluorocarbon beclomethasone dipropionate inhalation on small airways: assessment with functional helical thin-section computed tomography. J Allergy Clin Immunol 1999; 104:S258-S267.
107. Dolovich M. Inhalation technique and inhalation devices. In: Pauwels R, Lofdahl CG, O’Byrne P, eds. Beta2-Agonists in Asthma Treatment. New York: Marcel Dekker, 1997:229-255.
108. Dolovich M. Measurement of particle size characteristics of metered dose inhaler (MDI) aerosols. J Aerosol Med 1991; 4:251-264.
109. Borgström L, Bondesson E, Morén F, Trofast E, Newman SP. Lung deposition of budesonide inhaled via the Turbuhaler: a comparison with terbutaline sulphate in normal subjects. Eur Respir J 1994; 7: 69-73.
110. Engel T, Scharling B, Skovsted B, Heinig JH. Effects, side effects and plasma concentrations of terbutaline in adult asthmatics after inhaling from a dry powder inhaler device at different inhalation flows and volumes. Br J Clin Pharmac 1992; 33:439-444.
111. Borgström L, Newman S, Weisz AF, Morén F. Pulmonary deposition of inhaled terbutaline: comparison of scanning gamma camera and urinary excretion methods. J Pharm Sci 1992; 81:753-755.
112. Chang HK, Menon AS. Airflow dynamics in the human airways. In: Morén F, Dolovich MB, Newhouse MT, Newman SP, eds. Aerosols in Medicine: Principles, Diagnosis and Therapy. Amsterdam: Elsevier, 1993:85-116.
113. Coates G, Dolovich MB, Chamberlain MJ, Biello DR, Lavender JP. The use of radioactive aerosols inthe diagnosisof lungdisease. Ann CRMCC 1985; 18:344-346.
114. Chapman KR, Friberg K, Balter MS, Hyland RH, Alexander M, Abboud RT, Peters S, Jennings BH. Albuterol via Turbuhaler versus albuterol via pressurized metereddose inhaler in asthma. Ann Allergy Asthma Immunol 1997; 78:59-63.
115. Agertoft L, Pedersen S. Importance of the inhalation device on the effect of budesonide. Arch Dis Child 1993; 69:130-133.
116. Dubus JC, Rhem R, Dolovich M. In vitro characterization of salbutamol generic MDIs: delivery via small spacers (abstr). Eur Respir J 1998; 12: 65S.
117. Fowler SJ, Lipworth BJ. Therapeutic equivalence of inhaled salbutamol (letter). Thorax 2000; 55:347-348.
118. Kleerup EC, TashkinDP, ClineAC, Ekholm BP. Cumulative dose-response study of non-CFC propellant HFA 134a salbutamol sulfate metered-dose inhaler in patients with asthma. Chest 1996; 109:702-707.
119. Bleecker ER, Tinkelman DG, Ramsdell J, EkholmBP, KlingerNM, Colice GL, et al. Proventil HFA provides bronchodilation comparable to Ventolin over 12 weeks of regular use in asthmatics. Chest 1998; 113:283-289.
120. Tinkelman DG, Bleecker ER, Ramsdell J, EkholmBP, KlingerNM, Colice GL, et al. Proventil HFA and Ventolin have similar safety profiles during regular use. Chest 1998; 113:290-296.
121. Dockhorn RJ, Wagner DE, Burgess GL, Hafner KB, Letourneau K, Colice GL, et al. Proventil HFA provides protection from exercise-induced bronchoconstriction comparable to Proventil and Ventolin. Ann Allergy Asthma Immunol 1997; 79:85-88.
122. Hamid Q, Song Y, Kotsimbos TC, Minshall E, Bai T, Hegele RG, Hogg JC. Inflammation of small airways in asthma. J Allergy Clin Immunol 1997; 100:44-51.
123. 121a. Rinderknecht J, Shapiro L, Krauthammer M, Taplin G, Wasserman K, Uszler JM, Effros RM. Accelerated clearance of small solutes from the lungs in interstitial lung disease. Am Rev Respir Dis 1980; 121:105-117.
124. Dolovich M, Rhem R. In vitro comparison of a BDP HFA pMDI with CFC Beclovent ™. ERJ 1999; 14(suppl 30):197S, P1364.
125. Dolovich M, Rhem R. In vitro characterization of two BDP HFA pMDIs (abstr). J Aerosol Med 1999; 12(2):112.
126. Milanowski J, Qualtrough J, Perrin VL. Inhaled beclomethasone (BDP) with non-CFC propellant (HFA 134a) is equivalent to BDP-CFC for the treatment of asthma [see comments]. Respir Med 1999; 93:245-251.
127. Farmer IS, MiddleM, Savic J, Perrin VL, Herdman MJ. Therapeutic equivalence of inhaled beclomethasone dipropionate with CFC and non-CFC (HFA 134a) propellants both delivered via the Easibreathe inhaler for the treatment of paediatric asthma. Respir Med 2000; 94:57-63.
128. Dolovich M, Rhem R. In vitro comparison of 2 strengths of Beclazone, a beclomethasone dipropionate (BDP) HFA 134 pMDI, with CFC Beclovent and Becloforte. AJRCCM 2000; 161(3 Part 2):A33.
129. Zanen P, Go LT, Lammers J-WJ. The optimal particle size for parasympathicolytic aerosols in mild asthmatics. Int J Pharmaceut 1995; 114(1):111-115.
130. Zanen P, Go LT, Lammers JW. Optimal particle size for beta 2 agonist and anticholinergic aerosols in patients with severe airflow obstruction [see comments]. Thorax 1996; 51(10):977-980.
131. Zanen P, Go LT, Lammers JW. The efficacy of a low-dose, monodisperse parasympathicolytic aerosol compared with a standard aerosol from a metered-dose inhaler. Eur J Clin Pharmacol 1998; 54(1):27-30.
132. Kim CS, Garcia L. Delivery characteristics of albuterol powder aerosol by Rotahaler. J Aerosol Med 1993; 6:199-211.
133. Pitcairn G, Lunghetti G, Ventura P, Newman S. A comparison of the lung deposition of salbutamol inhaled from a new dry powder inhaler at two inhaled flow rates. Int J Pharm 1994; 102:11-18.
134. Dolovich M, Rhem R, Rashid F, Bowen B, Coates G, Hill M. Lung deposition of albuterol sulphate from the Dura Dryhaler on normal adults. Am J Respir Crit Care Med 1996; 153:A62.
135. Olsson B, Asking L. Critical aspects of the function of inspiratory flow driven inhalers. J Aerosol Med 1994; 7(suppl 1):S43-S47.
136. Chew NY, Chan HK. Influence of particle size, air flow, and inhaler device on the dispersion of mannitol powders as aerosols. Pharm Res 1999; 16:1098-1103.
137. Dolovich M, Vanzieleghem M, Hidinger KG, Newhouse MT. Influence of inspiratory flow rate on the response to terbutaline sulphate inhaled by the Turbuhaler. Am Rev Respir Dis 1988; 137:433.
138. Ruffin RE, Dolovich MB, Wolff RK, Newhouse MT. The effect of preferential deposition of histamine in the human airway. Am Rev Respir Dis 1978; 117:485-592.
139. Ruffin R, DolovichM, Oldenburg, Jr. FA, Newhouse M. Preferential deposition of inhaled isoproterenal and propranolol in asthmatic patients. Chest 1981; 80S:904-907.
140. Hindle M, Newton DA, Chrystyn H. Investigations of an optimal inhaler technique with the use of urinary salbutamol excretion as a measure of relative bioavailability to the lung. Thorax 1993; 48(6):607-610.
141. Lipworth BJ, Clark DJ. Early lung absorption profile of non-CFC salbutamol via small and large volume plastic spacer devices. Br J Clin Pharmacol 1998; 46:45-48.
142. Martonen TB, Yang Y, Dolovich M. Definition of airway composition within gamma camera images. J Thorac Imaging 1994; 9(3):188-197.
143. Phipps PR, Gonda I, Bailey DL, Borham P, Bautovich G, Anderson SD. Comparisons of planar and tomographic gamma scintigraphy to measure the penetration index of inhaled aerosols. Am Rev Respir Dis 1989; 139(6):1516-1523.
144. Fleming JS, Hashish AH, Conway JH, Nassim MA, Holgate ST, Halson P et al. Assessment of deposition of inhaled aerosol in the respiratory tract of man using threedimensional multimodality imaging and mathematical modeling. J Aerosol Med 1996; 9(3):317-327.
145. Rhodes CG, Hughes JMB. Pulmonary studies using positron emission tomography. Eur Respir J 1995; 8: 1011-1017.
146. Dolovich M, Nahmias C, Coates G. Unleashing the PET: 3D imaging of the lung. In: Byron P, Dalby R, Farr SJ, eds. Proceedings of Respiratory Drug Delivery VII. Raleigh, NC: Serentec Press, 2000:215-230.
147. Smaldone GS. Factors in measurement of dose by gamma scintigraphy. J Aerosol Med 1996; 9:S69-S76.
148. Langenback EG, Foster WM, Bergofsky EH. Calculating concentration of inhaled radiolabelled particles from external gamma counting: external counting efficiency and attenuation coefficient of thorax. J Toxicol Environ Health 1989; 26:139-152.
149. Cross CD, Hornof WJ, Koblik PH, Fisher PE. Aerosol deposition: practical considerations of methodology for the direct measurement of aerosol delivery to the lung bronchiolar-alveolar surfaces. J Aerosol Med 1993; 5:39-45.
150. Fok TF, Al-Essa M, Kirpalani H, Monkman S, Bowen B, Coates G, Dolovich M. Estimation of pulmonary deposition of aerosol using gamma scintigraphy. J Aerosol Med 1999; 12:9-15.
151. Dolovich MB, Rhem R, Coates G. Defining and quantitating peripheral lung deposition using radiolabelled tracers and 2D imaging. Eur Respir J 2000; 16(suppl 31):62S, P560.
152. Fleming JS, Halson P, Conway J, Moore E, Nassim MA, Hashish AH, et al. Threedimensional description of pulmonary deposition of inhaled aerosol using data from multimodality imaging. J Nucl Med 1996; 37(5):873-877.
153. Berridge MS, Heald DL. In vivo characterization of inhaled pharmaceuticals using quantitative positron emission tomography. J Clin Pharmacol 1999; 39:25S-29S.
154. Dolovich M, Nahmias C, Thompson M, Yuki S, Frietag A, Coates G. Positron emission tomographic PET) imaging of the lung in cystic fibrosis: 3D assessment of the distribution of inhaled therapy. Am J Respir Crit Care Med 1999; 159(Part 2):A687.
155. Bergstrom M, Cass LM, Valind S, Westerberg G, Lundberg EL, Gray S, Bye A, Langstrom B. Deposition and disposition of [11C]zanamivir following administration as an intranasal spray. Evaluation with positron emission tomography. Clin Pharmacokinet 1999; 36(suppl 1):33-39.
156. Warren SW, Taylor G, Godfrey C, Cote G, Hill M. Gamma scintigraphic evaluation of dry powder beclomethasone dipropionate (BDP) from an investigational Spiros Inhaler: effect of inspiratory flow profile on pulmonary drug deposition. Am J Respir Crit Care Med 1999; 159(Part 2): 118.
157. Pitcairn G, Lunghetti G, Ventura P, Newman S. A comparison of the lung deposition of salbutamol inhaled from a new dry powder inhaler, at two inhaled flow rates. Int J Pharm 1994; 102:11-18.
158. Vidgren M, Arppe J, Vidgren P, Vainio P, SilvastiM, Tukiainen H. Pulmonary deposition of 99mTc-labelled salbutamol particles in healthy volunteers after inhalation from a metered-dose inhaler and from a novel multiple-dose inhaler. STP Pharm Sci 1994; 4:29-32.
159. Warren SJ, Taylor G. Effect of inhalation flow profiles on the deposition of radiolabelled BDP from a novel dry powder inhaler (DPI, Clickhaler™), a conventional metered dose inhaler (MDI) and MDI plus spacer In: Dalby RN, Byron PR, Farr SJ, eds. Proceedings Respiratory Drug Delivery VI. Buffalo Grove, IL: Interpharm Press, Inc., 1998: 453-455.
160. Warren SJ, Taylor G. Gamma scintigraphic evaluation of a novel budesonide dry powder inhaler (Clickhaler™) (abstr). AAPS Pharm Sci 1999; 1:2243.
161. Mackie AE, Moss J, McDowall JE, Moss J, Ventresca GP, Bye A. Pharmacokinetics of fluticasone propionate inhaler from the Diskhaler™ and Diskus™ powder devices in healthy volunteers (abstr). Br J Clin Pharmacol 1997; 43:540-541P.
162. Falcoz C, Mackie AE, Horton J, Ventresca GP, Brown A, Field E, Harding SM, Wire P, Bye A. Pharmacokinetics of fluticasone propionate inhaled from the Diskhaler ™ and the Diskus™ powder devices in asthmatic patients (abstr). J Allergy Clin Immunol 1997; 99 (suppl):S505.
163. Pitcairn GR, Lankinen T Seppala OP, Newman SP. Pulmonary drug delivery from the Taifun dry powder inhaler is relatively independent of the patient’s inspiratory effort. J Aerosol Med 2000; 13:97-104.
164. Pitcairn G, Lim J, Hollingworth A, Newman SP. Scintigraphic assessment of drug delivery from the Ultrahaler™ dry powder inhaler. J Aerosol Med 1997; 10:295-306.